Logo for Insmed Incorporated

Insmed Investor Relations Material

Latest events

Logo for Insmed Incorporated

Q4 2023

Insmed
Logo for Insmed

Q4 2023

22 Feb, 2024
Logo for Insmed

Q3 2023

26 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.